Regional interaction between myocardial sympathetic denervation, contractile dysfunction, and fibrosis in heart failure with preserved ejection fraction: 11C-hydroxyephedrine PET study

[1]  N. Tamaki,et al.  Impaired Myocardial Sympathetic Innervation Is Associated with Diastolic Dysfunction in Heart Failure with Preserved Ejection Fraction: 11C-Hydroxyephedrine PET Study , 2017, The Journal of Nuclear Medicine.

[2]  N. Tamaki,et al.  Delayed contrast-enhanced computed tomography in patients with known or suspected cardiac sarcoidosis: A feasibility study , 2017, European Radiology.

[3]  C. Lücke,et al.  Extracellular Volume Fraction for Characterization of Patients With Heart Failure and Preserved Ejection Fraction. , 2016, Journal of the American College of Cardiology.

[4]  M. Javadi,et al.  Sympathetic nerve damage and restoration after ischemia-reperfusion injury as assessed by 11C-hydroxyephedrine , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[5]  S. Nekolla,et al.  Multiparametric Molecular Imaging Provides Mechanistic Insights into Sympathetic Innervation Impairment in the Viable Infarct Border Zone , 2015, The Journal of Nuclear Medicine.

[6]  Wolfgang A. Linke,et al.  Heart failure with preserved ejection fraction , 2014, Pflügers Archiv - European Journal of Physiology.

[7]  A. Curtis,et al.  Regional myocardial sympathetic denervation predicts the risk of sudden cardiac arrest in ischemic cardiomyopathy. , 2014, Journal of the American College of Cardiology.

[8]  Scott D Flamm,et al.  Standardized cardiovascular magnetic resonance (CMR) protocols 2013 update , 2013, Journal of Cardiovascular Magnetic Resonance.

[9]  Yoichi M. Ito,et al.  Paradoxical Interventricular Septal Motion as a Major Determinant of Late Gadolinium Enhancement in Ventricular Insertion Points in Pulmonary Hypertension , 2013, PloS one.

[10]  Scott D Flamm,et al.  Standardized image interpretation and post processing in cardiovascular magnetic resonance: Society for Cardiovascular Magnetic Resonance (SCMR) Board of Trustees Task Force on Standardized Post Processing , 2013, Journal of Cardiovascular Magnetic Resonance.

[11]  H. Shirato,et al.  Identification and further differentiation of subendocardial and transmural myocardial infarction by fast strain-encoded (SENC) magnetic resonance imaging at 3.0 Tesla , 2011, European Radiology.

[12]  Igor Klem,et al.  Assessment of myocardial scarring improves risk stratification in patients evaluated for cardiac defibrillator implantation , 2011, Journal of the American College of Cardiology.

[13]  Jeroen J. Bax,et al.  Cardiac sympathetic denervation assessed with 123-iodine metaiodobenzylguanidine imaging predicts ventricular arrhythmias in implantable cardioverter-defibrillator patients. , 2010, Journal of the American College of Cardiology.

[14]  M. Cerqueira,et al.  Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study. , 2010, Journal of the American College of Cardiology.

[15]  Y. Akutsu,et al.  The Significance of Cardiac Sympathetic Nervous System Abnormality in the Long-Term Prognosis of Patients with a History of Ventricular Tachyarrhythmia , 2008, Journal of Nuclear Medicine.

[16]  L. Brewster,et al.  Prognostic value of myocardial 123I-metaiodobenzylguanidine (MIBG) parameters in patients with heart failure: a systematic review. , 2008, European heart journal.

[17]  J. Fleg,et al.  Heart failure with preserved ejection fraction. , 2006, The New England journal of medicine.

[18]  R. Kim,et al.  Delayed enhancement cardiovascular magnetic resonance assessment of non-ischaemic cardiomyopathies. , 2005, European heart journal.

[19]  K. Nakajima,et al.  Changes in cardiac sympathetic nerve innervation and activity in pathophysiologic transition from typical to end-stage hypertrophic cardiomyopathy. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[20]  R. Kim,et al.  Relationship of contractile function to transmural extent of infarction in patients with chronic coronary artery disease. , 2003, Journal of the American College of Cardiology.

[21]  Heiko Mahrholdt,et al.  Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy. , 2002, Journal of the American College of Cardiology.

[22]  H. Huikuri,et al.  Sudden death due to cardiac arrhythmias. , 2001, The New England journal of medicine.

[23]  S. Nekolla,et al.  Relationship between altered sympathetic innervation, oxidative metabolism and contractile function in the cardiomyopathic human heart; a non-invasive study using positron emission tomography. , 2001, European heart journal.

[24]  G. Schmidt,et al.  Extent of cardiac sympathetic neuronal damage is determined by the area of ischemia in patients with acute coronary syndromes. , 2000, Circulation.

[25]  D. Goldstein,et al.  Myocardial perfusion and sympathetic innervation in patients with hypertrophic cardiomyopathy. , 2000, Journal of the American College of Cardiology.

[26]  M. Hadamitzky,et al.  Regional patterns of myocardial sympathetic denervation in dilated cardiomyopathy: an analysis using carbon-11 hydroxyephedrine and positron emission tomography , 1999, Heart.

[27]  D. Zipes,et al.  Regional cardiac sympathetic denervation in patients with ventricular tachycardia in the absence of coronary artery disease. , 1993, Journal of the American College of Cardiology.

[28]  M. Akers,et al.  Abnormal I-123 metaiodobenzylguanidine myocardial washout and distribution may reflect myocardial adrenergic derangement in patients with congestive cardiomyopathy. , 1988, Circulation.

[29]  W. Kannel,et al.  The natural history of congestive heart failure: the Framingham study. , 1971, The New England journal of medicine.

[30]  K. Nakajima,et al.  Heterogeneity of cardiac sympathetic nerve activity and systolic dysfunction in patients with hypertrophic cardiomyopathy. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.